Please provide your email address to receive an email when new articles are posted on . AUSTIN, Texas — At the National Kidney Foundation Spring Clinical Meetings, Matthew R. Weir, MD, spoke about ...
Galenica Group today announced that Relypsa, Inc., a Vifor Pharma Company, has received approval from the US Food and Drug Administration (FDA) for a supplemental New Drug Application (sNDA) with ...
tHE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (chmp) OF THE EUROPEAN MEDICINES AGENCY (ema) HAS RECOMMENDED MARKETING AUTHORISATION FOR pATIROMER (BRAND NAME vELTASSA ®) IN all 31 eu/eea ...
ST. GALLEN, Switzerland, Sept. 24, 2024 /PRNewswire/ -- CSL Vifor today announced that Japan's Ministry of Health and Labor Welfare (MHLW) has granted its partner, Zeria Pharmaceutical Co., Ltd.
The Scottish Medicines Consortium (SMC) has ruled that there’s not enough evidence to support NHS funding of Vifor Pharma’s Veltassa for excess potassium in the blood (hyperkalaemia), even though ...
ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma today announced positive findings in the completed phase-IIIb DIAMOND trial of ...
The U.S. Food and Drug Administration today approved Veltassa (patiromer for oral suspension) to treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high. "Too ...
The drug will be funded on the NHS to treat hyperkalaemia The National Institute for Health and Care Excellence has given its stamp of approval for NHS use of Vifor Pharma’s hyperkalaemia drug ...
Relypsa announced that the Food and Drug Administration (FDA) has approved Veltassa (patiromer) for oral suspension, indicated for the treatment of hyperkalemia. The approval is based on clinical ...
Please provide your email address to receive an email when new articles are posted on . Veltassa (patiromer) for oral suspension is now available for prescription to patients with hyperkalemia in the ...
(RTTNews) - Vifor Pharma announced positive outcome of the phase-IIIb DIAMOND trial of Veltassa in heart failure patients with either manifest hyperkalemia or with a history of hyperkalemia while ...
The Scottish Medicines Consortium (SMC) has ruled that there’s not enough evidence to support NHS funding of Vifor Pharma’s Veltassa for excess potassium in the blood (hyperkalaemia), even though ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results